Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy

被引:1
作者
Mo, Juanmei [1 ]
Luo, Min [1 ]
Cui, Jiandong [1 ]
Zhou, Shaozhang [2 ]
机构
[1] Chinese Peoples Liberat Army, Hosp 303, Dept Oncol, Nanning, Peoples R China
[2] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Chemotherapy, Nanning, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2015年 / 8卷 / 11期
关键词
ERCC1; ERCC2; polymorphism; gastric cancer; treatment outcome; CELL LUNG-CANCER; NUCLEOTIDE EXCISION-REPAIR; MESSENGER-RNA EXPRESSION; DNA-REPAIR; OVARIAN-CARCINOMA; SURVIVAL; PATHWAY; MARKERS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted a prospective study to analyze whether ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 gene polymorphisms could serve as potential biomarkers for the prognosis of gastric cancer. A total of 228 patients with pathologically proven gastric cancer and receiving platinum-based chemotherapy were recruited from our hospital between October 2009 and October 2011. The ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 polymorphisms were genotyped using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. Conditional logistic regression analysis revealed that patients carrying the CA and AA genotypes of ERCC1 rs3212986 polymorphism showed a poorer response to chemotherapy compared to the CC genotype (CA vs. CC: OR = 0.28, 95% CI = 0.06-0.98, P = 0.04; AA vs. CC: OR = 0.49, 95% CI = 0.06-0.98, P = 0.01). Moreover, the CA+ AA genotype of ERCC1 rs3212986 polymorphism showed a significantly poorer response to chemotherapy (CA+ AA vs. CC: OR = 0.49, 95% CI = 0.27-0.90). Patients with the AA genotype of ERCC1 rs3212986 polymorphism had a longer overall survival time when compared with the CC genotype (34.91 months vs. 51.19 months, log-rank P = 0.003). The AA genotype of ERCC1 rs3212986 polymorphism in gastric cancer patients was correlated with a higher risk of death from varying causes by the Cox proportional hazards model, compared to the CC genotype (HR = 6.19, 95% CI = 1.42-30.60). In conclusion, the ERCC1 rs3212986 polymorphism was found to influence the response to chemotherapy and overall survival of gastric cancer patients.
引用
收藏
页码:15065 / 15071
页数:7
相关论文
共 27 条
  • [1] [Anonymous], EST INC MORT PREV WO
  • [2] Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma
    Bonneau, Claire
    Rouzier, Roman
    Geyl, Caroline
    Cortez, Annie
    Castela, Mathieu
    Lis, Raphael
    Darai, Emile
    Touboul, Cyril
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 112 - 120
  • [3] Chen WH, 2014, CHINA PLOS ONE, V9
  • [4] Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair
    Coin, Frederic
    Oksenych, Valentyn
    Egly, Jean-Marc
    [J]. MOLECULAR CELL, 2007, 26 (02) : 245 - 256
  • [5] The eukaryotic nucleotide excision repair pathway
    Costa, RMA
    Chiganças, V
    Galhardo, RD
    Carvalho, H
    Menck, CFM
    [J]. BIOCHIMIE, 2003, 85 (11) : 1083 - 1099
  • [6] Duffaud F, 2000, B CANCER, V87, P881, DOI 10.1093/jnci/92.3.205
  • [7] The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif
    Enzlin, JH
    Schärer, OD
    [J]. EMBO JOURNAL, 2002, 21 (08) : 2045 - 2053
  • [8] HaiYu, 2015, INT J CLIN EXP PATHO, V8, P4106
  • [9] ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Kalikaki, Aristea
    Voutsina, Alexandra
    Koutsopoulos, Anastasios
    Papadaki, Chara
    Sfakianaki, Maria
    Yachnakis, Emmanouel
    Xyrafas, Alexandros
    Kotsakis, Athanasios
    Agelaki, Sofia
    Souglakos, John
    Mavroudis, Dimitrios
    Georgoulias, Vassilis
    [J]. CANCER INVESTIGATION, 2015, 33 (04) : 107 - 113
  • [10] Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer
    Liang, R.
    Lin, Y.
    Liu, Z. H.
    Liao, X. L.
    Yuan, C. L.
    Liao, S. N.
    Li, Y. Q.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2015, 14 (02): : 5804 - 5811